What are the likely IVF/ICSI outcomes if there is a discrepancy between serum AMH and FSH levels? A multicenter retrospective study.

[1]  M. Eijkemans,et al.  Antimüllerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization. , 2015, Fertility and sterility.

[2]  K. Tremellen,et al.  Serum anti‐Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan , 2015, The Australian & New Zealand journal of obstetrics & gynaecology.

[3]  Z. Rosenwaks,et al.  Value of antimüllerian hormone as a prognostic indicator of in vitro fertilization outcome. , 2014, Fertility and sterility.

[4]  G. Serour,et al.  Impact of antimüllerian hormone assays on the outcomes of in vitro fertilization: a prospective controlled study. , 2014, Fertility and sterility.

[5]  C. Rongières,et al.  To what extent does anti-mullerian hormone contribute to a better prediction of live birth after IVF? , 2014, Journal of Assisted Reproduction and Genetics.

[6]  B. Lunenfeld,et al.  Can anti-Müllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation? , 2013, Reproductive biomedicine online.

[7]  J. Belaisch-Allart,et al.  Pronostic en fécondation in vitro des patientes ayant une AMH basse et une FSH normale , 2012 .

[8]  P. Cohen-Bacrie,et al.  [Low circulating anti-Müllerian hormone and normal follicle stimulating hormone levels: which prognosis in an IVF program?]. , 2012, Gynecologie, obstetrique & fertilite.

[9]  E. Anckaert,et al.  The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments , 2012, Human reproduction.

[10]  N. Raine-Fenning,et al.  Anti-Müllerian hormone: clairvoyance or crystal clear? , 2012, Human reproduction.

[11]  R. Anderson,et al.  Measuring anti-Müllerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? , 2012, Maturitas.

[12]  A. McConnachie,et al.  External validation of nomogram for the decline in serum anti-Müllerian hormone in women: a population study of 15,834 infertility patients. , 2011, Reproductive biomedicine online.

[13]  Sesh Kamal Sunkara,et al.  Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. , 2011, Human reproduction.

[14]  A. McConnachie,et al.  Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients. , 2011, Fertility and sterility.

[15]  F. Broekmans,et al.  AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. , 2011, Human reproduction update.

[16]  D. Barad,et al.  Discordances between follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) in female infertility , 2010, Reproductive biology and endocrinology : RB&E.

[17]  B. Mol,et al.  The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome , 2010, Current opinion in obstetrics & gynecology.

[18]  A. Volpe,et al.  Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). , 2010, Human reproduction update.

[19]  A. P. Walsh,et al.  Ovarian reserve screening in infertility: practical applications and theoretical directions for research. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[20]  H. Yarali,et al.  Antagonist/letrozole protocol in poor ovarian responders for intracytoplasmic sperm injection: a comparative study with the microdose flare-up protocol. , 2009, Fertility and sterility.

[21]  Vanessa N. Weitzman,et al.  Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes. , 2009, Fertility and sterility.

[22]  B. Mol,et al.  The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. , 2009, Fertility and sterility.

[23]  G. Barrenetxea,et al.  Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. , 2008, Fertility and sterility.

[24]  D. Gardner,et al.  Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol? , 2008, Fertility and sterility.

[25]  F. Broekmans,et al.  Expected poor ovarian response in predicting cumulative pregnancy rates: a powerful tool. , 2008, Reproductive biomedicine online.

[26]  B. Fauser,et al.  Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? , 2008, Reproductive biomedicine online.

[27]  S. Nelson,et al.  Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. , 2007, Human reproduction.

[28]  J. Habbema,et al.  Predicting ongoing pregnancy chances after IVF and ICSI: a national prospective study. , 2007, Human reproduction.

[29]  A. Volpe,et al.  Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. , 2007, Human reproduction.

[30]  G. Zielhuis,et al.  Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. , 2007, Fertility and sterility.

[31]  R. Gilchrist,et al.  Anti-Müllerian hormone as a predictor of IVF outcome. , 2007, Reproductive biomedicine online.

[32]  A. Volpe,et al.  Serum anti-Mullerian hormone throughout the human menstrual cycle. , 2006, Human reproduction.

[33]  B. Mol,et al.  A systematic review of tests predicting ovarian reserve and IVF outcome. , 2006, Human reproduction update.

[34]  F. Broekmans,et al.  Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. , 2006, The Journal of clinical endocrinology and metabolism.

[35]  O. Shebl,et al.  Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. , 2006, Human reproduction.

[36]  E. Margalioth,et al.  Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome , 2005 .

[37]  J. Habbema,et al.  Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. , 2005, Fertility and sterility.

[38]  J. Habbema,et al.  The antral follicle count is a better marker than basal follicle-stimulating hormone for the selection of older patients with acceptable pregnancy prospects after in vitro fertilization. , 2005, Fertility and sterility.

[39]  D. Seifer,et al.  Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. , 2004, Fertility and sterility.

[40]  R. Fanchin,et al.  Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. , 2003, Human reproduction.

[41]  J. Toner.  Ovarian reserve, female age and the chance for successful pregnancy. , 2003, Minerva ginecologica.

[42]  D. Seifer,et al.  Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. , 2002, Fertility and sterility.

[43]  P. Pearson,et al.  The variability of female reproductive ageing. , 2002, Human reproduction update.

[44]  B. Fauser,et al.  Antimüllerian hormone serum levels: a putative marker for ovarian aging. , 2002, Fertility and sterility.

[45]  M. Perloe,et al.  Strategies for ascertaining ovarian reserve among women suspected of subfertility. , 2000, International journal of fertility and women's medicine.

[46]  J. Dumoulin,et al.  Elevated levels of basal estradiol-17beta predict poor response in patients with normal basal levels of follicle-stimulating hormone undergoing in vitro fertilization. , 1998, Fertility and sterility.

[47]  Joan K. Morris,et al.  Factors that affect outcome of in-vitro fertilisation treatment , 1996, The Lancet.

[48]  M. Faddy,et al.  Ovary and ovulation: A model conforming the decline in follicle numbers to the age of menopause in women , 1996 .

[49]  J. Hall,et al.  Prognostic value of day 3 estradiol on in vitro fertilization outcome. , 1995, Fertility and sterility.

[50]  S. Muasher,et al.  Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. , 1991, Fertility and sterility.